Skip to main content
Article thumbnail
Location of Repository

Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination

By Frédérique Fenneteau, Jacques Turgeon, Lucie Couture, Véronique Michaud, Jun Li and Fahima Nekka
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2000). A priori Prediction of Tissue:Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery.
  2. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. JC l i nI n v e s t1995,
  3. (2005). and Osterberg T: In vitro models for the blood-brain barrier. Toxicol In Vitro
  4. (2001). and Serabjit-Singh CS: Rational use of in vitro Pglycoprotein assays in drug discovery. J Pharmacol Exp Ther
  5. (2005). and von Moltke LL: Interaction of warfarin with drugs, natural substances, and foods.
  6. (2006). Bjorquist A and Ungell AL: Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.
  7. (2003). Blood-brain barrier efflux transport.
  8. (2003). Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
  9. (1985). Cardiotoxicity of domperidone. lancet
  10. (1985). Cardiotoxicity of intravenous domperidone. Lancet
  11. (1998). Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res
  12. (2002). Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet
  13. (2003). Dietary effects on drug metabolism and transport. Clin Pharmacokinet
  14. (1999). Domperidone: A peripherally Acting Dopamine2-receptor antagonist. Ann Pharmacol
  15. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res
  16. (2004). EC: Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev
  17. (2004). Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse bloodbrain barrier. Cancer Res
  18. (1979). Handbook of physiology: the Cardiovascular System
  19. (2003). Importance of P-glycoprotein for drug disposition in humans.
  20. (2004). Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999, 79:108–113. 6 . M u r a m a t s uT ,J o h n s o nD
  21. (2002). Interspecies considerations in the evaluation of human food safety for veterinary drugs. AAPS Pharm Sci
  22. (1997). Limited oral biovailability abd active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci
  23. (1995). Multidrug resistance and the role of P-glycoprotein knockout mice.
  24. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc Natl Acad Sci
  25. (1970). On the blood content of guineapig tissues. Pharmacology
  26. (1981). On the pharmacokinetics of domperidone in animals and
  27. (2005). P-glycoprotein and mutlidrug resistanceassociated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther
  28. (2003). Physiologically Based Pharmacokinetic (PBPK) Modeling of Dispposition of Epiroprim in Humans.
  29. (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.
  30. (2002). Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report
  31. (1950). Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. Proc Soc Exp Biol Med
  32. (1991). Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. Drug Metab Dispos
  33. (2004). Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res
  34. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsomes. Drug Met Disp
  35. (2002). Prediction of Pharmacokinetics prior to in Vivo Studies. II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition.
  36. (2004). Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care
  37. (2005). Protection Agency: Exposure Assessment Tools and Models.
  38. (2001). Quantitative exposure assessment: application of physiologically-based pharmacokinetic (PBPK) modeling of low-dose, long-term exposures of organic acid toxicant in the brain. Environ Toxicol Pharmacol
  39. (2002). Resolution of P-glycoprotein and non P-glycoprotein effects on drug permeability using intestinal tissus from mdr1a(-/-) mice.
  40. (1985). Reyntjens AJ and Lake-Bakaar G: Cardiac arrest after treatment with intravenous domperidone.
  41. (1997). Rhomberg LR and Beliles RP: Physiologically parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health
  42. (1994). Robanus-Maandag EC and te Riele HP, et al: Disruption of the mouse mdr1a P-glycoprotein gene to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell
  43. (2000). Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm Res
  44. (2001). Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica
  45. (2000). Schellens JH and Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
  46. (2001). Schoenlein K and Theil F: Prediction of Adipose Tissue: Plasma Partition Coefficients for Structurally Unrelated Drugs.
  47. (1996). Substantial excretion of digoxin via the intestinal mucosa and prevention of long term digoxin accumulation in the brain by mdr1a P-glycoprotein.
  48. (2006). The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev
  49. (2002). The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos
  50. (1990). The role of Pglycoprotein in determining the oral absorption and clearance of the
  51. (2001). Upregulation of the transport system for TNFalpha at the blood-brain barrier. Arch Physiol Biochem
  52. (2003). Whole Body Pharmacokinetic Models. Clin Pharmacokinet

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.